Background: Antiretroviral therapy (ART) introduced during primary HIV infection followed by treatment interruption (TI) is postulated to enhance virologic control through induction of HIV-specific CD4+ T cells, which foster virus-specific CD8+ T cells that suppress virus replication. This hypothesis was evaluated in 21 subjects enrolled in AIDS Clinical Trials Group 709, a substudy of AIDS Clinical Trials Group 371, which prospectively evaluated subjects who received ≥1 year of ART initiated in acute or recent HIV infection followed by TI.
Methods: Lymphoproliferation was assessed by [methyl-3H] thymidine incorporation and HIV-specific CD8+ T-cell interferon-gamma responses by enzyme-linked immunospot-forming assays. Virologic success was defined as sustained viral load <5000 copies per milliliter for 24 weeks after TI.
Results: HIV-specific lymphoproliferative responses were detected at least once in 5 (24%) of 21 subjects, were generally transient, and were unrelated to HIV-specific interferon-gamma responses (P > 0.4). HIV-specific CD8+ interferon-gamma responses increased after 48 weeks of ART (P = 0.03), but failed to predict virologic success (P = 0.18). Compared with seronegative subjects, lymphoproliferation to Candida, cytomegalovirus, and alloantigens was similar in HIV-infected subjects during ART, but lower during TI (P ≤ 0.04).
Conclusions: HIV-specific CD8+ T-cell interferon-gamma responses expand during ART following primary HIV infection, but are not related to HIV-specific lymphoproliferative responses nor virologic success. Impaired non-HIV antigen-specific lymphoproliferation associated with TI suggests this strategy could be deleterious.
From the *Division of Infectious Diseases, Department of Medicine, University of Colorado Denver, Aurora, CO; †Department of Biostatistics, Harvard School of Public Health, Boston, MA; ‡Division of Infectious Diseases, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY; and §Department of Medicine, University of California San Francisco and San Francisco Veterans Administration Medical Center, San Francisco, CA.
Received for publication January 11, 2011; accepted May 16, 2011.
Supported by the AIDS Clinical Trials Group, under the National Institute of Allergy and Infectious Diseases grants AI-68636, AI-38858, AI 69450, AI-38855, AI-069511, AI-69432, and AI-68634. In addition, study drugs were provided by the manufacturers including GlaxoSmithKline, Bristol Myers Squibb, Agouron/Pfizer.
Correspondence to: Elizabeth Connick, MD, Division of Infectious Diseases, Department of Medicine, University of Colorado Denver, 12700 East 19th Avenue, Box B168, Aurora, CO 80045 (e-mail: firstname.lastname@example.org).
Primary HIV infection is often associated with a flu-like illness and high-titer viremia that gradually declines over a period of weeks to months to a quasi-steady state known as the virus setpoint.1 Severity of clinical symptoms2,3 and virus setpoint after primary infection1 are predictive of rates of disease progression suggesting that early virus-host interactions may determine disease outcome. Rosenberg et al4 reported that antiretroviral therapy (ART) initiated in primary HIV infection followed by treatment interruption (TI) resulted in viral loads under 5000 copies per milliliter for sustained periods of time in 7 of 8 subjects, a significantly larger proportion than was observed to have virus set-points below 5000 copies per milliliter in a cohort of untreated seroconverters. Individuals treated during primary HIV infection had substantially more vigorous virus-specific CD4+ T-cell responses than individuals with chronic treated or untreated HIV infection,4,5 and those who maintained low viral loads during TI experienced expansions in HIV-specific CD8+ T-cell interferon-gamma responses.4 In light of these data and the known helper functions provided by CD4+ T cells to cytotoxic CD8+ T cells,6 it was hypothesized that the mechanism underlying reduced viremia after treatment of acute HIV infection was the induction and preservation of HIV-specific CD4+ T-cell responses, which fostered robust antiviral CD8+ T-cell responses.
AIDS Clinical Trials Group (ACTG) 371 was implemented to test the efficacy of ART followed by TI in acute and recent HIV infection and results of this study have been published elsewhere.7 ACTG 709 was an immunology substudy of ACTG 371 that was designed to evaluate the impact of early ART and TI on HIV-specific CD4+ and CD8+ T-cell responses. The primary hypotheses underlying ACTG 709 were that (1) early treatment of HIV infection results in robust HIV-specific lymphoproliferative responses; (2) these responses are associated with vigorous HIV-specific CD8+ T-cell interferon-gamma responses; and (3) HIV-specific CD8+ T-cell responses correlate with low-level viremia during TI. Secondary analyses examined the impact of this strategy on lymphoproliferative responses to non-HIV microbial antigens and alloantigens.
HIV-infected subjects were individuals enrolled into ACTG 371,7 a prospective trial of ART initiated in acute or recent HIV infection, who agreed to participate in a substudy (ACTG 709). This required donation of additional blood at study entry, 48 weeks after initiation of therapy, 4 weeks after TIs, and 24 weeks after TIs. Acute infection was defined as having a plasma HIV RNA concentration more than 2000 copies per milliliter within 14 days of study entry and either a negative enzyme-linked immunosorbent assay (ELISA) or a positive ELISA but a negative or indeterminate western blot (CDC/ASTPHLD criteria) or a positive ELISA and western blot in conjunction with either a negative ELISA or a plasma HIV RNA concentration less than 2000 copies per milliliter in the 30 days before entry. Recent infection was defined as a positive ELISA and western blot within the 14 days before entry, but a negative ELISA or plasma HIV RNA concentration less than 2000 copies per milliliter within the 31-90 days before entry or a positive ELISA and western blot and a nonreactive detuned ELISA in patients with more than 200 CD4+ cells per microliter all within the 21 days before study entry. If plasma HIV RNA was below 50 copies per milliliter and CD4+ T cells >200 cells per cubic millimeter after 52 weeks of treatment, ART was interrupted. If viremia rebounded >50,000 copies per milliliter on 2 consecutive measurements or above 5000 copies per milliliter on 3 consecutive measurements, the cycle of treatment and TI was repeated. The primary endpoint of virologic success was defined as achieving a viral load less than 5000 copies per milliliter at 24 weeks after either the first or second TI. Thirty-three (83%) of the proposed total of 40 subjects were enrolled in ACTG 709, and 21 (64%) of these individuals underwent TI and are included in this analysis. Seronegative control subjects were laboratory workers tested annually for HIV antibodies. The study was performed in accordance with federal human experimentation guidelines; all subjects provided informed consent in accordance with local institutional review boards.
Peripheral Blood Specimens
Peripheral blood specimens were collected in sodium heparin-containing tubes (BD Vacutainer, San Diego, CA) and shipped overnight to the University of Colorado AIDS Clinical Trials Group Immunology Laboratory. Specimens obtained at the University of Colorado were held overnight at room temperature to maintain comparable handling conditions.8 Peripheral blood mononuclear cells (PBMCs) were isolated by ficoll-hypaque density centrifugation and used immediately in lymphocyte proliferation assays or cryopreserved for future studies.
Lymphocyte Proliferation Assays
Lymphocyte proliferation was assessed by [methyl-3H] thymidine incorporation using 4 replicate wells as previously described9 using the following antigens: Candida albicans (20 μg/mL, Greer Laboratories, Lenoir, NC), tetanus toxoid, (0.5 Lfu/mL, Connaught Laboratories, Willowdale, Ontario), HIV-1 p24 or control antigen (1 μg/mL, Protein Sciences, Meriden, CT), HIV-1 env2-3 SF2 or control antigen, (0.5 μg/mL, Chiron Corporation, Emeryville, CA), Mycobacterium avium complex (MAC) antigen (0.5 μg/mL Statens Seruminstitut, Copenhagen, Denmark), cytomegalovirus (CMV) or control antigen (1/50 dilution, provided by Dr Adriana Weinberg, University of Colorado, Denver, CO),10 and alloantigens consisting of pooled PBMC from 15 unrelated donors that had been previously gamma-irradiated, cryopreserved, and stored in liquid nitrogen. Phytohemagglutinin (5 μg/mL, Sigma, St Louis, MO) was included as a positive control. Stimulation index (SI) was calculated as median counts per minute in the stimulated wells divided by median counts per minute in relevant control wells. If the observed SI was less than 1, then a value of 1 was assigned.
Enzyme Linked Immuno-Spot Assays for HIV-Specific Interferon-Gamma Responses
Cryopreserved PBMC were thawed, rested overnight, and seeded onto nitrocellulose bottom plates (Millipore, Burlington, MA) coated with 10 mg/mL anti-IFN-g (Mabtech, Stockholm, Sweden) at a concentration of 100,000 cells per well in media (AIM-V; Life Technologies, Grand Island, NY) supplemented with 10% human AB serum (Gemini Bio-Products, Calabasas, CA). HIV-1 pooled peptides (AIDS Research and Reference Reagent Program, Bethesda, MD) were added to duplicate wells at a final concentration of 2 mg/mL: MN Env (15-mer peptides), HXB2 Gag (15-mer peptides), Clade B Concensus Nef (15-mer peptides), HXB2 Pol (20-mer peptides), and Concensus B Rev (15-mer peptides). A positive control well treated with phytohemagglutinin (20 μg/mL) was included in each assay. Plates were incubated at 37°C for 48 hours, stained with 2 μg/mL biotinylated 7-b6-1 (Mabtech), and spots were developed using Vectastain kit (Vector Laboratories, Burlingame, CA) and 3-amino-9-ethylcarbazole (Sigma). Spot forming cells (SFCs) per well were determined by visual inspection and manual counting. HIV-specific interferon-gamma responses were calculated by subtracting the mean SFC of unstimulated wells from the mean SFC in peptide-stimulated wells. Total HIV-specific interferon-gamma responses were determined by summing individual antigen-specific responses. Results were scaled by multiplying by 10 and expressed as SFC per 106 PBMC; a positive response was defined as ≥20 SFC/106 PBMC and also at least 2-fold above levels of SFC in unstimulated wells. CD8 depletion was performed using CD8 Dynabeads, (Invitrogen Dynal AS, Oslo, Norway) and antibody staining confirmed depletion of >95% of CD8+ cells in all cases.
Immunologic measurements are summarized using medians and rank-based correlations. Groups are compared using the Wilcoxon rank-sum and Fisher exact tests. Lymphoproliferative responses at each timepoint (log10 SI) are compared with responses in seronegative subjects using generalized estimating equations to account for repeated measurements in seronegative subjects. Changes in proportions are compared using McNemar test. No adjustments are made for multiple comparisons.
Clinical characteristics and outcomes of the 21 study subjects enrolled in ACTG 709 who underwent TI were similar to those of the 73 subjects enrolled in the parent study who interrupted therapy.7 The majority (95%) were males, the median age was 36 years at enrollment, and most were white (86%). Median baseline CD4+ T-cell count was 599 cells per cubic millimeter, and median baseline HIV RNA concentration was 79,500 copies per milliliter. Eight (38%) subjects were acutely and 13 (62%) were recently infected. Nine (43%) met criteria for virologic success during the first TI and 1 additional subject achieved virologic success during a second TI.
Lymphocyte Proliferative Responses
Lymphocyte proliferative responses to microbial antigens and alloantigens are shown in Figure 1. Five (24%) HIV-infected subjects had detectable HIV-specific lymphoproliferative responses, defined as a SI ≥3 at any time point to HIV env or gag antigen, and no HIV-specific lymphoproliferative responses were detected in control subjects. Previous studies have demonstrated that the lymphoproliferative responses induced by these antigens are primarily mediated by CD4+ T cells.11,12 HIV-specific lymphoproliferative responses were low, with a maximum SI of 14. Only 1 subject responded to both HIV antigens. HIV-specific responses were transient in all but 1 subject who had responses to the same antigen twice. One subject developed new HIV-specific lymphoproliferative responses during the first and another during the second TI. Four (80%) of 5 subjects with HIV-specific lymphoproliferative responses achieved virologic success after 24 weeks of TI, compared with 6 (38%) of 16 without HIV-specific lymphoproliferative responses (P = 0.15). When analysis was restricted to lymphoproliferative responses detected before TI (n = 3), 100% achieved virologic success compared with 7 (39%) of 18 subjects who did not harbor HIV-specific lymphoproliferative responses (P = 0.09). Two (25%) subjects with acute infection and 3 (23%; P = 1.0) with recent infection had HIV-specific lymphoproliferative responses. Neither baseline CD4+ T cells (P = 0.35) nor baseline viral load (P = 0.13) significantly correlated with proliferative responses to HIV, although median baseline viral load tended to be lower in those with HIV-specific lymphoproliferative responses (52,400 copies/mL) compared with those without lymphoproliferative responses (148,200 copies/mL).
Responses to non-HIV microbial antigens and alloantigens were more robust than those to HIV (Figs. 1C-G). At baseline, HIV-infected subjects had significantly lower lymphocyte proliferative responses to tetanus toxoid, MAC, Candida, and CMV antigens compared with 12 seronegative subjects (P ≤ 0.02). Increases in median lymphocyte proliferative responses to all non-HIV microbial antigens were observed after 48 weeks of ART, but responses to tetanus and MAC antigens remained lower compared with those in seronegative subjects (P ≤ 0.01). Responses to microbial antigens and alloantigens waned after 4 weeks of TI and all were significantly lower at this time point compared with seronegative controls (P ≤ 0.04). In the subset of subjects studied at week 24, the majority of whom achieved virologic success, microbial antigen, and alloantigen responses were not significantly impaired compared with control subjects. Individuals who reached the study endpoint of virologic success after 24 weeks of TI tended to have higher lymphocyte proliferative responses to microbial antigens at all time points compared with those who were not successful in reaching the study endpoint (Fig. 1); these differences were most pronounced at baseline for CMV (P = 0.001) and Candida (P = 0.07), and at week 4 of the first TI for MAC (P = 0.015). There was no significant difference in microbial antigen or alloantigen lymphoproliferative responses at any time point between individuals treated during acute versus recent HIV-1 infection.
HIV-Specific CD8+ T-Cell Responses
HIV-specific interferon-gamma responses are shown in Figure 2. CD8 depletion of PBMC in 5 subjects demonstrated ≥97% reduction in interferon-gamma responses in all instances, consistent with prior studies.13 At baseline, 6 (32%) of 19 subjects demonstrated virus-specific interferon-gamma responses. Responses were seen to nef (21%), env (16%), and gag (11%); the mean number of HIV antigens recognized by the 6 responders at baseline was 1.7. The proportion of subjects with detectable HIV-specific interferon-gamma responses increased at week 48 to 75% (9 of 12 subjects; P = 0.03 compared with 3 of 12 subjects at baseline). Subjects at week 48 harbored responses to nef (25%), env (42%), gag (58%), and pol (33%); the mean number of HIV antigens recognized by the 9 responders was 2.2. Enrollment during acute versus recent HIV infection was not related to the magnitude or breadth of interferon-gamma responses either at baseline (P = 0.76 and P = 0.84, respectively) or week 48 (P = 0.96 and P = 0.86, respectively). There was no significant relationship between HIV-specific lymphoproliferative responses and magnitude or breadth of interferon-gamma responses at week 48 (P = 1.0 and P = 0.68, respectively). Furthermore, there was no significant relationship between virologic success during TI and interferon-gamma responses at week 48 (P = 0.18) (Fig. 2).
Enzyme-linked immunospot-forming assay results were available on 12 subjects during TI; assays could not be performed in 9 subjects during TI because PBMC were not received in the laboratory, there were insufficient cells, or cells had poor viability. Figure 3 summarizes representative enzyme-linked immunospot-forming assay results and viral loads from 3 subjects with virologic success (Fig. 3A-C) and 3 with virologic failure (Fig. 3D-F). All subjects except A had documented increases in HIV-specific interferon-gamma responses during TI. There was no apparent temporal relationship between increases in interferon-gamma responses and viral load. Indeed, low-level viremia was evident in all subjects with virologic success before increases in HIV-specific interferon-gamma responses occurred, and more than 5-fold increases in interferon-gamma responses were seen in subjects D and E, but did not result in virologic success. The magnitude of interferon-gamma responses during TI varied among subjects, but there was no obvious difference between subjects with virologic success and those with failure.
ACTG 709 is one of the largest studies to date to evaluate prospectively the impact of ART followed by TI on HIV-specific responses in acutely and recently infected individuals. This study was designed to investigate the findings of Rosenberg et al,4 which were subsequently confirmed by Kaufmann et al,14 that the majority of treated seroconverters with robust HIV-specific lymphoproliferative responses during ART were able to maintain viral loads below 5000 copies per milliliter for at least 6 months after 1 or more TIs. The present study is distinct from these 2 previous studies in that subjects were not limited to those with robust HIV-specific lymphoproliferative responses, but instead all seroconverters who received early ART and underwent TI were included. Thus, the present study provides information on the impact of this strategy on immune responses in a wider population of seroconverters than those 2 previous studies. Results of the present study revealed the following: (1) a minority of subjects treated during primary HIV infection had detectable HIV-specific lymphoproliferative responses; (2) HIV-specific CD8+ T-cell interferon-gamma responses increased in magnitude and breadth during 1 year of suppressive ART but were not related to HIV-specific lymphoproliferative responses; and (3) HIV-specific CD8+ T-cell interferon-gamma responses were not associated with virologic success during TI. Collectively, these data do not support the hypotheses that early treatment of HIV infection frequently results in robust HIV-specific lymphoproliferative responses, that induction of robust HIV-specific lymphoproliferative responses in individuals treated during primary infection augments HIV-specific CD8+ T-cell interferon-gamma responses, or that virus-specific CD8+ T-cell interferon-gamma responses mediate viral control during TI.
HIV-specific lymphoproliferative responses were observed in 24% of subjects in the present study and in most instances were transient. The frequency of lymphoproliferative responses in individuals treated during primary infection has varied widely in other studies ranging from 25% to 100% of those treated for 1 year.4,15,16 Differences in types and concentrations of HIV antigens used in assays may partially account for these discrepancies. The strength of our study is that seronegative subjects who were studied concurrently demonstrated no evidence of HIV-specific responses, thereby confirming the specificity of the assay. Lymphoproliferative responses in the present study may have been blunted because specimens for immune function assays were shipped overnight or held for 24 hours before performance of the assays, procedures that we have previously shown reduce lymphoproliferative responses.8 The abundance of lymphoproliferative responses to non-HIV antigens, however, indicates that loss of lymphoproliferative responses was relative and not absolute. Importantly, robust lymphoproliferative responses are reduced, but not ablated by shipment of specimens,8 suggesting that most individuals in our study did not develop robust HIV-specific lymphoproliferative responses despite early initiation of ART.
All 3 subjects who harbored HIV-specific lymphoproliferative responses before TI achieved virologic success, whereas only 39% of the 18 subjects without HIV-specific lymphoproliferative responses maintained low-level viremia for at least 6 months during TI. These findings are consistent with previous studies in acute4,15 and chronic HIV infection17,18 that have demonstrated an association between the presence of HIV-specific lymphoproliferative responses, which are largely mediated by CD4+ T cells,11,12 and virologic success upon TI. Initially, many interpreted this as evidence of “immune control” of HIV replication.4 Nevertheless, multiple lines of evidence including data from this study suggest that HIV-specific CD4+ T cells do not control viremia. HIV-specific CD4+ T cells are highly susceptible to HIV infection in vivo.19 Although short bursts of viremia boost virus-specific CD4+ T cells, the majority of these cells are depleted in association with loss of HIV-specific lymphoproliferative responses during prolonged TI,20 consistent with the transient nature of HIV-specific lymphoproliferative responses we observed. Furthermore, induction of HIV-specific lymphoproliferative responses through therapeutic vaccination in a previous study of individuals treated during primary infection failed to reduce viremia during TI.21 Subjects with HIV-specific lymphoproliferative responses in the present study tended to have lower baseline viral loads than those without HIV-specific responses, and lower baseline viral load was also related to virologic success in the parent study.7 Similarly, Kaufmann et al14 reported that the major predictor of low-level viremia during the first TI was a low viral load before initiation of ART. Collectively, these data suggest that preserved HIV-specific lymphoproliferative responses are the consequence of a relatively less virulent HIV infection and not the cause of it. An entry criterion for both studies of Rosenberg et al4 and Kaufmann et al14 was a robust HIV-specific lymphoproliferative response (SI ≥ 10) before TI.4 Selection of subjects with less virulent HIV infection may explain why more subjects achieved virologic success in their studies, 88% and 57%, respectively, compared with ACTG 371 (40%)7.
HIV-specific CD8+ T-cell interferon-gamma responses increased in both magnitude and breadth during 1 year of ART, but were not predictive of virologic success, similar to what has been reported in other studies of TI in primary infection.5,14,15 Importantly, the present study illustrates that CD8+ interferon-gamma responses can be augmented during TI even in subjects without vigorous HIV-specific lymphoproliferative responses before TI. Marked epitope-specific and allele-specific differences in the ability of HIV-specific CD8+ T cells to neutralize HIV-1 in vitro have been observed despite similar interferon-gamma responses,22 suggesting that interferon-gamma responses are not reflective of CD8+ T-cell antiretroviral activity. More recently, the interaction between peptide and major histocompatibility complex class I alleles has been linked to durable virologic control in chronic HIV infection.23 Associations between low-level viremia and HIV-specific CD8+ T-cell maturation levels,24,25 cytokine profiles,26,27 and release of a soluble, noncytotoxic factor28 have been described as well. Whether these characteristics of CD8+ T cells account for the virologic control seen in subjects in the present study and whether they are modifiable by early initiation of ART are unanswered questions.
If timing of initiation of ART in primary infection is critically related to preservation of lymphoproliferative responses or magnitude of interferon-gamma responses, one would anticipate that subjects treated earliest would have the most vigorous immune responses. In the present study, there was no evidence for more robust immune responses to HIV or other antigens in those treated in acute versus recent infection. In the parent study ACTG 3717 and in the study by Kaufmann et al,14 the timing of initiation of ART was not related to durability of virologic control during TI. Because subjects were not randomized to treatment according to disease stage, it is not possible to derive definitive conclusions from these observations. Nevertheless, these data suggest that there is no dramatic enhancement of antigen-specific lymphocyte proliferative responses or HIV-specific CD8+ T-cell responses from early initiation of ART in primary HIV infection.
Impairments in lymphoproliferative responses to all non-HIV microbial antigens were demonstrated at baseline in HIV-infected subjects compared with seronegative subjects. ART initiated during primary infection was associated with normalization of lymphoproliferative responses to the ubiquitous antigens Candida and CMV, whereas neither tetanus nor MAC-specific lymphoproliferative responses normalized on ART, consistent with findings in chronic infection.29,30 Importantly, lymphoproliferative responses to all non-HIV microbial antigens and alloantigens worsened during TI and were impaired 4 weeks after TI compared with those in seronegative controls. This is the first study to report the impact of TI on lymphoproliferative responses to multiple non-HIV microbial antigens and alloantigens in individuals treated during acute HIV infection. These findings contrast with those of Rosenberg et al4 who reported that tetanus-specific lymphoproliferative responses were not altered in the context of TI and concluded from these limited data that the intervention was safe. Progressive impairments in lymphoproliferation to HIV antigens, recall antigens, alloantigens, and mitogens were the first functional defects described in association with HIV infection.31 These impairments correlate with CD4+ T cells but are also predictive of disease progression independent of viral load and CD4+ T-cell count.32 Taken together, these data suggest that TI in individuals treated during early HIV infection results in significant immune impairments.
Enthusiasm for TI as a strategy to reduce antiretroviral drug use has waned substantially over the past 5 years. TI during chronic HIV infection resulted in worse clinical outcomes in subjects enrolled in the SMART study.33 In addition, observational studies suggest that initiation of ART at CD4+ T-cell counts above 500 cells per cubic millimeter is associated with better clinical outcomes than when ART is initiated at conventional CD4+ T-cell threshold levels.34 Data from the present study demonstrating impairments in antigen-specific lymphoproliferative responses during TI in subjects with primary infection further support the notion that continued ART is beneficial even in early disease. New initiatives to enhance HIV prevention by early treatment of all individuals with ART35 further weigh against strategies that use TI. Recent data from a randomized controlled study of 9 months of ART followed by TI versus standard of care treatment for primary HIV infection suggest that early treatment confers a 4-month delay in initiation of ART,36 consistent with observations from uncontrolled study of Kaufmann et al14 that virologic control conferred by early ART is not durable.14 If additional data from larger randomized controlled studies confirm this modest benefit, it seems unlikely that this strategy will continue to be pursued. Nevertheless, the improvement in virologic control conferred by ART in primary infection remains unexplained. A better understanding of the mechanisms underlying the transient virologic control conferred by early treatment and TI could nonetheless provide important insight into HIV pathogenesis and potentially lead to development of novel and more durable therapies to treat and prevent HIV infection.
We are deeply grateful to the research subjects and the ACTG sites and staff who participated in this study. We also acknowledge the assistance of the AIDS Research and Reference Reagent Program, which provided HIV peptides for the enzyme-linked immunospot-forming assays, and Monique Givens and Arshia Mian for technical assistance in performance of lymphocyte proliferation assays.
1. Mellors JW, Kingsley LA, Rinaldo CR Jr, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med
2. Pedersen C, Lindhardt BO, Jensen BL, et al. Clinical course of primary HIV infection: consequences for subsequent course of infection. BMJ
3. Schacker TW, Hughes JP, Shea T, et al. Biological and virologic characteristics of primary HIV infection. Ann Intern Med
4. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature
5. Altfeld M, Rosenberg ES, Shankarappa R, et al. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med
6. Matloubian M, Concepcion RJ, Ahmed R. CD4+
T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol
7. Volberding P, Demeter L, Bosch RJ, et al. Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment. AIDS
8. Betensky RA, Connick E, Devers J, et al. Shipment impairs lymphocyte proliferative responses to microbial antigens. Clin Diagn Lab Immunol
9. Lederman MM, Connick E, Landay A, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis
10. Weinberg A, Spritzler J, Nokta M, et al. In vitro cell-mediated immune responses of human immunodeficiency virus-infected and -uninfected individuals to whole cytomegalovirus antigens and their subunits. Clin Vaccine Immunol
11. Palmer BE, Boritz E, Blyveis N, et al. Discordance between frequency of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-producing CD4(+) T cells and HIV-1-specific lymphoproliferation in HIV-1-infected subjects with active viral replication. J Virol
12. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4+
T cell responses associated with control of viremia. Science
13. Bull M, Lee D, Stucky J, et al. Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials. J Immunol Methods
14. Kaufmann DE, Lichterfeld M, Altfeld M, et al. Limited durability of viral control following treated acute HIV infection. PLoS Med
15. Goujard C, Marcellin F, Hendel-Chavez H, et al. Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 Randomized Study. AIDS Res Hum Retroviruses
16. Rizzardi GP, Lazzarin A, Pantaleo G. Potential role of immune modulation in the effective long-term control of HIV-1 infection. J Biol Regul Homeost Agents
17. Jacobson JM, Pat Bucy R, Spritzler J, et al. Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068. J Infect Dis
18. Plana M, Garcia F, Oxenius A, et al. Relevance of HIV-1-specific CD4+
helper T-cell responses during structured treatment interruptions in patients with CD4+
T-cell nadir above 400/mm3. J Acquir Immune Defic Syndr
19. Douek DC, Brenchley JM, Betts MR, et al. HIV preferentially infects HIV-specific CD4+
T cells. Nature
20. Seth N, Kaufmann D, Lahey T, et al. Expansion and contraction of HIV-specific CD4 T cells with short bursts of viremia, but physical loss of the majority of these cells with sustained viral replication. J Immunol
21. Kinloch-de Loes S, Hoen B, Smith DE, et al. Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis
22. Chen H, Piechocka-Trocha A, Miura T, et al. Differential neutralization of human immunodeficiency virus (HIV) replication in autologous CD4 T cells by HIV-specific cytotoxic T lymphocytes. J Virol
23. Pereyra F, Jia X, McLaren PJ, et al, for the International HIV Controllers Study. The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation. Science
24. Ellefsen K, Harari A, Champagne P, et al. Distribution and functional analysis of memory antiviral CD8 T cell responses in HIV-1 and cytomegalovirus infections. Eur J Immunol
25. Hess C, Altfeld M, Thomas SY, et al. HIV-1 specific CD8+ T cells with an effector phenotype and control of viral replication. Lancet
26. Daucher M, Price DA, Brenchley JM, et al. Virological outcome after structured interruption of antiretroviral therapy for human immunodeficiency virus infection is associated with the functional profile of virus-specific CD8+ T cells. J Virol
27. Almeida JR, Price DA, Papagno L, et al. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med
28. Barker E, Mackewicz CE, Reyes-Teran G, et al. Virological and immunological features of long-term human immunodeficiency virus-infected individuals who have remained asymptomatic compared with those who have progressed to acquired immunodeficiency syndrome. Blood
29. Connick E. Immune reconstitution in HIV-1-infected individuals treated with potent antiretroviral therapy. J Investig Dermatol Symp Proc
30. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+
T cell homeostasis and function in advanced HIV disease. Science
31. Clerici M, Stocks NI, Zajac RA, et al. Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+
cell numbers and clinical staging. J Clin Invest
32. Dolan MJ, Clerici M, Blatt SP, et al. In vitro T cell function, delayed-type hypersensitivity skin testing, and CD4+
T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus. J Infect Dis
33. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+
count-guided interruption of antiretroviral treatment. N Engl J Med
34. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med
35. Dieffenbach CW, Fauci AS. Universal voluntary testing and treatment for prevention of HIV transmission. JAMA
36. Hogan C, DeGruttola V, Daar E, et al. A finite course of ART during early HIV-1 infection modestly delays need for subsequent ART initiation: ACTG A5217, the SETPOINT Study [abstract 134]. Paper presented at: 17th Conference on Retroviruses and Opportunistic Infections Program and Abstracts; February 16-19, 2010; San Francisco, CA.